Class / Patent application number | Description | Number of patent applications / Date published |
514190900 | Cyclopeptide utilizing | 42 |
20100240595 | Improved Antitumoral Treatments - The present invention relates to combinations of Aplidine with Gemcitabine, and the use of these combinations in the treatment of cancer. | 09-23-2010 |
20100305044 | PEPTIDE ANTI-TUMOR AGENT - Disclosed herein are isolated, purified peptides, biologically active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials. | 12-02-2010 |
20110009338 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE - A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein. | 01-13-2011 |
20110034399 | Liquid and Freeze Dried Formulations - The present invention relates to stable parenteral formulations comprising a new class of compounds, which is a non proteinic compound, a method for preparing such formulations as well as the use of certain compounds for stabilizing these formulations. | 02-10-2011 |
20110224151 | Polymeric Micelle Composition for Treatment of Resistant Cancer and Preparation Method of the Same - Disclosed are a polymer micelle composition for treatment of resistant cancer cells that contains an amphiphilic double block copolymer and taxane and a P-glycoprotein inhibitor of cyclosporin as its active ingredients, and a method of preparing the same. Said polymer micelle composition for treatment of cancer resistant cells is accumulated in cancer tissue at high concentrations, and has the advantages that it exhibits superior anti-cancer effects for the cancer cells that have exhibited resistance due to over-expression of P-glycoprotein by the taxane anticancer agent in said cancer tissue, and does not cause hypersensitive reactions due to the use of a solubilizer. | 09-15-2011 |
20110269698 | Novel Cyclic Pentadepsipeptide Derivative and Fusarium Strain Producing The Same - Disclosed is a | 11-03-2011 |
20110269699 | CANCER THERAPY - The invention provides therapy for treating cancers, such as Bcl-2 | 11-03-2011 |
20110306563 | MACROLACTONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF CANCER - The present invention relates to the use of a compound of the formula (I), wherein X and Y independently of one another are OH, O—(C | 12-15-2011 |
20120046234 | THERAPEUTIC COMPOUNDS - The invention provides compounds of formula I, II, and III as defined herein, as well as salts thereof. The compounds may have activity as anti-proliferative agents. | 02-23-2012 |
20120094927 | THERAPY FOR MLL-REARRANGED LEUKEMIA - Provided are methods for treating MLL-rearranged ALL by administering to a patient an HDAC inhibitor alone or in combination with a DNA demethylating agent. Also provided are methods of treating MLL-rearranged infant ALL. Methods of treating cells by these agents are also provided. Additionally, disclosed is a method for screening for compounds capable to treat MLL-rearranged ALL, in particular, MLL-rearranged infant ALL. In one embodiment, the HDAC inhibitor is romidepsin. | 04-19-2012 |
20120115793 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 05-10-2012 |
20120122799 | CYCLIC PEPTIDE ANTITUMOR AGENTS - Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells. | 05-17-2012 |
20120149648 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease. | 06-14-2012 |
20120178700 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 07-12-2012 |
20120322743 | Compositions and Methods for Diagnosing and Treating Melanoma - Described herein are compositions and methods for the diagnosis, prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated with melanoma, as well as various nucleic acid molecules relating thereto or derived therefrom. | 12-20-2012 |
20130029918 | METHODS FOR REDUCING VEIN IRRITATION - The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions. | 01-31-2013 |
20130065837 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER - Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide. | 03-14-2013 |
20130072439 | PEPTIDOMIMETIC MACROCYCLES - Disclosed are peptidomimetic macrocycles comprising a helix, such as an alpha helix, and methods of using such macrocycles for the treatment of disease such as cancer. In other aspects, the peptidomimetic macrocycle comprises an a,a-disubstituted amino acid, or may comprise a crosslinker linking the a-positions of at least two amino acids or at least one of said two amino acids may be an a,a-disubstituted amino acid. Further included is the targeting of components of the Wnt signaling pathway such as the Tcf4-/3-catenin complex. | 03-21-2013 |
20130150309 | CYCLIZED PEPTIDOMIMETIC SMALL MOLECULE INHIBITORS OF THE WDR5 AND MLL1 INTERACTION - Cyclic peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed. | 06-13-2013 |
20130150310 | Compositions and Methods for Treatment of Cancer - The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention and also administering a effective amount of a chemotherapeutic agent. | 06-13-2013 |
20130157962 | METHODS FOR INHIBITING GROWTH OF PROLACTIN-RESPONSIVE CANCER CELLS WITH CYCLOSPORINE A OR OTHER CYCLOPHILIN INHIBITORS - Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin. | 06-20-2013 |
20130172267 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 - The present application relate to cyclic depsipeptides, or derivatives thereof, having the formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7. | 07-04-2013 |
20130184225 | ROMIDEPSIN FORMULATIONS AND USES THEREOF - Provided herein are formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation is a combination of romidepsin and mannitol. | 07-18-2013 |
20130210745 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES - Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 08-15-2013 |
20130231292 | Synergistic anti-proliferation activity of TAS-108 with mTOR inhibitors against cancer cells - The invention provides methods and compositions for inhibiting tumor growth in a mammal. The methods comprise administering to the mammal a synergistic combination of (7α)-21-[4-[(Diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate and a synergistic chemotherapeutic drug. The combination of the compounds more than additively inhibits growth of tumor cells. | 09-05-2013 |
20130244950 | COMBINATION THERAPY FOR CHEMORESISTANT CANCERS - Methods of treating, preventing or managing triple negative breast cancer (TNBC) or clear cell renal cell carcinoma (ccRCC) are disclosed. The methods encompass the administration of an HDAC inhibitor romidepsin in combination with a cytidine analog. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed. | 09-19-2013 |
20130244951 | TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES - The present invention is directed to the use of rapamycin derivatives for use in treating solid tumors, optionally in combination with a chemotherapeutic agent. | 09-19-2013 |
20130345146 | NEAR-INFRARED ELECTROMAGNETIC MODIFICATION OF CELLULAR STEADY-STATE MEMBRANE POTENTIALS - Systems and methods are disclosed herein for applying near-infrared optical energies and dosimetries to alter the bioenergetic steady-state trans-membrane and mitochondrial potentials (ΔΨ-steady) of all irradiated cells through an optical depolarization effect. This depolarization causes a concomitant decrease in the absolute value of the trans-membrane potentials ΔΨ of the irradiated mitochondrial and plasma membranes. Many cellular anabolic reactions and drug-resistance mechanisms can be rendered less functional and/or mitigated by a decrease in a membrane potential ΔΨ, the affiliated weakening of the proton motive force Δp, and the associated lowered phosphorylation potential ΔGp. Within the area of irradiation exposure, the decrease in membrane potentials ΔΨ will occur in bacterial, fungal and mammalian cells in unison. This membrane depolarization provides the ability to potentiate antimicrobial, antifungal and/or antineoplastic drugs against only targeted undesirable cells. | 12-26-2013 |
20140005122 | GEMCITABINE COMBINATION THERAPY | 01-02-2014 |
20140073587 | RESISTANCE BIOMARKERS FOR HDAC INHIBITORS - Provided herein are methods for identifying a cancer patient at risk for resistance to an HDAC inhibitor therapy, comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in the sample; quantifying a level of the TSPYL5 expression in the sample, wherein a high level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, correlates with resistance to the HDAC inhibitor therapy; and applying the correlation to identify the cancer patient at risk for resistance to the HDAC inhibitor therapy. Also provided is a method for identifying a cancer patient with an increased likelihood of a positive clinical response to an HDAC inhibitor therapy comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in said sample; quantifying a level of said TSPYL5 expression in said sample, wherein a low level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, identifies said cancer patient with an increased likelihood of a positive clinical response to said HDAC inhibitor therapy. Related methods and compositions are also provided. | 03-13-2014 |
20140100172 | Cancer Imaging and Treatment - Provided herein are compounds useful for diagnostic imaging and/or therapeutic purposes. Each compound comprises a ligand for the chemokine receptor CXCR4, which has a binding affinity for the CXCR4 receptor, measured as IC50 in the presence of | 04-10-2014 |
20140256650 | RESISTANCE BIOMARKERS FOR HDAC INHIBITORS - Provided herein are methods for identifying a cancer patient at risk for resistance to an HDAC inhibitor therapy, comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in the sample; quantifying a level of the TSPYL5 expression in the sample, wherein a high level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, correlates with resistance to the HDAC inhibitor therapy; and applying the correlation to identify the cancer patient at risk for resistance to the HDAC inhibitor therapy. Also provided is a method for identifying a cancer patient with an increased likelihood of a positive clinical response to an HDAC inhibitor therapy comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in said sample; quantifying a level of said TSPYL5 expression in said sample, wherein a low level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, identifies said cancer patient with an increased likelihood of a positive clinical response to said HDAC inhibitor therapy. Related methods and compositions are also provided. | 09-11-2014 |
20140371159 | IN VITRO METHOD FOR MODIFYING THE DEPLETION PROFILE OF TREG CELLS PRESENT IN A TOTAL SPLENOCYTE POPULATION OF A BIOLOGICAL SAMPLE BY MEANS OF THE ISOLATION, CULTURING AND EXPOSURE THEREOF TO AN ATP AND POLYMIXIN B MEDIUM - In vitro method to modify the deplexion profile of Treg Cells present in a total splenocyte population of a biological sample comprising isolating, cultivating and submitting the splenocyte at a ATP medium and polymyx B, where the splenocytes at concentrations of Polymyxin B in the range 0.1 μg/ml to 100 μg/ml, and combined use of Polymyxin B and ATP to prepare a medicament useful in the treatment tumor or cancer mammals, where cancer is melamine. | 12-18-2014 |
20150051157 | ROMIDEPSIN FORMULATIONS AND USES THEREOF - Provided herein are formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation is a combination of romidepsin and mannitol. | 02-19-2015 |
20150065434 | CYCLIC PEPTIDE INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE 1 - Provided herein are cyclic peptide inhibitors of lysine-specific demethylase 1. These cyclic peptides have the potential to treat cancer, diabetes, cardiovascular disease, and neurological disorders. | 03-05-2015 |
20150105328 | PEPTOID-PEPTIDE HYBRIDS AND THEIR USE - The invention concerns peptoid-peptide hybrids that may act as protein interaction inhibitors (PPIIs). Another aspect of the invention concerns a method for treating a disorder (e.g., an oncologic disorder) in a human or animal subject, comprising administering an effective amount of a peptoid-peptide hybrid (a peptoid body) of the invention, or a composition comprising a peptoid-peptide hybrid, to the subject in need thereof. Another aspect of the subject invention concerns a method for killing or inhibiting the growth of cells (e.g., cancer cells or malaria-infected cells), comprising contacting a cancer cell in vitro or in vivo with an effective amount of a peptoid-peptide hybrid, or a composition comprising the peptoid-peptide hybrid. Another aspect of the invention concerns a method for producing a peptoid-peptide hybrid. | 04-16-2015 |
20150329488 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY - Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein. | 11-19-2015 |
20160030507 | RESISTANCE BIOMARKERS FOR HDAC INHIBITORS - Provided herein are methods for identifying a cancer patient at risk for resistance to an HDAC inhibitor therapy, comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in the sample; quantifying a level of the TSPYL5 expression in the sample, wherein a high level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, correlates with resistance to the HDAC inhibitor therapy; and applying the correlation to identify the cancer patient at risk for resistance to the HDAC inhibitor therapy. Also provided is a method for identifying a cancer patient with an increased likelihood of a positive clinical response to an HDAC inhibitor therapy comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in said sample; quantifying a level of said TSPYL5 expression in said sample, wherein a low level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, identifies said cancer patient with an increased likelihood of a positive clinical response to said HDAC inhibitor therapy. Related methods and compositions are also provided. | 02-04-2016 |
20160060300 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 03-03-2016 |
20160067303 | ROMIDEPSIN FORMULATIONS AND USES THEREOF - Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer. | 03-10-2016 |
20160067304 | ROMIDEPSIN FORMULATIONS AND USES THEREOF - Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer. | 03-10-2016 |
20160069887 | BIOMARKERS FOR PROGNOSIS - The invention relates to biomarkers for determining the prognosis of cancer patients. By determining the level of the biomarker HR23B in the cell or patient, and optionally determining the levels of one or more of the biomarkers HDAC6, LC3 and HSP90, the invention provides a method for determining the susceptibility of a cell or a patient of interest to entering an autophagocytic state upon treatment with a drug. The invention also provides a method of determining susceptibility of a cell or patient to treatment with a drug. Entering an autophagocytic state is thought to be a tumour cell survival mechanism, whereby the tumour cell avoids apoptosis. The methods of the invention may therefore be helpful for determining whether a patient should be treated and for determining the prognosis upon drug treatment. | 03-10-2016 |